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INTRODUCTION
Despite an improvement in the treatment and remission
rate for patients with acute myeloid leukemia (AML), only
30-40% of patients show long-term survival (1). Modern
induction chemotherapy will result in complete remission
in 50-90% of patients with de novo disease, but between
10 and 25% of patients will have primary refractory disease
and the majority of those who gain remission will relapse
within 3 yr of diagnosis (2). Treatment of relapsed leukemia
is difficult and well-controlled trials in this group of patients
are uncommon.
Combination therapy with fludarabine phosphate (F-AMP)
and cytarabine (ara-C) has been advocated as a potentially
useful chemotherapeutic regimen for the treatment of relapsed
AML. This recommendation arises from the observation that
F-AMP potentiates the intracellular accumulation of the active
metabolite, ara-C 5′ triphosphate (ara-CTP) in leukemic cells
(3), thereby increasing the cytotoxic effect of high-dose ara-
C, one of the most useful agents in the treatment of AML (4,
5). Gandhi et al. (3, 6) demonstrated that the combination
of fludarabine and ara-C resulted in a significant increase in
intracellular retention of ara-CTP. Prior to fludarabine treat-
ment, granulocyte colony stimulating factor (G-CSF) increas-
es the fraction of cells in cycle when they are most vulnera-
ble to ara-C and enhances the incorporation of ara-C in to
DNA (7, 8). The FLAG regimen, which combines fludara-
bine, high dose ara-C, and G-CSF, has recently been used with
encouraging results in poor risk AML, myelodysplastic syn-
drome, and refractory or relapsed acute lymphoblastic leu-
kemia (ALL). In addition, the toxicity of the combination
was also low (9-15). 
In this study, we report the clinical effectiveness and toxi-
cities of FLAG chemotherapy in 61 patients with relapsed
or refractory AML. 
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The Clinical Outcome of FLAG Chemotherapy without Idarubicin 
in Patients with Relapsed or Refractory Acute Myeloid Leukemia
A refractory and resistant disease to conventional induction chemotherapy and
relapsed disease are considered as the most important adverse prognostic factors
for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with
relapsed or refractory AML were treated with the FLAG regimen that consisted of
fludarabine (30 mg/m
2, days 1-5), cytarabine (2.0 g/m
2, days 1-5) and granulocyte
colony-stimulating factor. Of the treated patients 29 patients (47.5%) achieved com-
plete remission (CR). Higher CR rates were observed for patients with a first or sec-
ond relapse as compared to patients with a primary refractory response or relapse
after stem cell transplantation (HSCT). There was a significant difference in the
response rates according to the duration of leukemia-free survival (pre-LFS) before
chemotherapy (P=0.05). The recovery time of both neutrophils (≥ ≥500/μ L) and pla-
telets (≥ ≥20,000/μ L) required a median of 21 and 18 days, respectively. Treatment-
related mortality (TRM) occurred in seven patients (11.4%), of which 71.4% of TRM
was caused by an invasive aspergillosis infection. After achieving CR, 18 patients
underwent consolidation chemotherapy and six patients underwent allogeneic HSCT.
In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and
well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemother-
apy has allowed intensive post-remission therapy including HSCT.
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MATERIALS AND METHODS
Patient characteristics 
Sixty-one eligible patients with refractory and relapsed
AML were treated with FLAG chemotherapy without idaru-
bicin between November 2003 and September 2007. To be
eligible for treatment with the FLAG regimen, patients had
to have a serum bilirubin level ≤2 mg/dL, a creatinine ≤2
mg/dL, and no evidence of cardiac dysfunction. The patients
were recruited from three National University Hospitals and
provided informed consent for this treatment.
The diagnosis and classification of AML were determined
according to the French-American-British (FAB) classifica-
tion and was confirmed by cytochemical staining and immu-
nophenotyping of the pretreatment marrow or blood sam-
ples. In addition, cytogenetic and molecular studies were
also performed in all patients. The enrolled patients consist-
ed of patients with M0 (n=1), M1 (n=6), M2 (n=19), M4
(n=9), M5 (n=10), M6 (n=5), M7 (n=1), mixed (n=4), and
secondary (n=6) AML. Six patients were identified as hav-
ing favorable cytogenetic abnormalities confined to t (8;21)
and inv (16), regardless of other abnormalities. In contrast,
15 patients were identified as having poor cytogenetic abnor-
malities confined to t (11p,12q), del (8), t (1:16), trisomy 8,
and Ph chromosome or other complex karyotypes. Moreover,
38 patients had normal karyotypes classified as intermediate
risk. Performance status (PS) was determined for each patient
according to World Health Organization (WHO) criteria;
40 patients were PS 0 or 1, 19 patients were PS 2, and 2 pa-
tients were in PS 3. 
Treatment protocol 
The primary induction regimen for remission was consist-
ed of idarubicin (IDA) (12 mg/m2/day IV over 30 min on
days 1-3) in combination with ara-C (100 or 200 mg/m2/day
IV continuously on days 1-7) or N4-behenoyl-1-D-arabino-
furanosyl-cytosine (BH-AC) (16) (age ≤40 yr, 300 mg/m2/
day IV over 4 hr on days 1-7; age >40 yr, 200 mg/m2/day).
The patients who achieved a remission were treated with
post-remission chemotherapy that included high-dose ara-C
(3 g/m2 IV every 12 hr on days 1, 3, and 5) as consolidation.
The patients who had a matched donor underwent allogene-
ic hematopoietic stem cell transplantation (HSCT).
The FLAG regimen consisted of fludararbine (30 mg/m2/
day IV over 30 min on days 1-5) in combination with ara-C
(2 g/m2/day IV over 4 hr on days 1-5; age between 50 and
60 yr or for those >60 yr the standard infusion doses of flu-
darabine and ara-C were reduced by one-third). G-CSF was
administered at 5 μ g/kg from day 0 until neutrophil recov-
ery (≥a neutrophil count of 500/μ L). 
Response assessment 
We considered complete remission (CR) to be morphologi-
cally normal marrow with ≤5% blasts concomitant with
normal peripheral and differential counts, including a neu-
trophil count ≥1×109/L and a platelet count ≥100×109/
L. Patients who did not respond to induction therapy were
considered to be in non-remission (NR), whereas patients
whose response could not be measured were considered to
be non-measurable (NM). 
Toxicity assessment 
Hematologic and non-hematologic toxicity were measured
and graded according to the criteria of the WHO. Addition-
al side effects and other adverse events not covered by the
WHO toxicity system were documented, including an assess-
ment of the severity of response to therapy. Post-chemother-
apy cytopenia was monitored by hematologic assessments
≥three times weekly, until neutrophil and platelet counts
recovered. Treatment-related mortality (TRM) was defined
as deaths resulting from a complication developing prior to
recovery from chemotherapy.
Statistical analysis 
Statistical analyses were performed using SPSS statistical
software version 12.0 (SPSS, Inc., Chicago, IL, U.S.A.). Com-
parisons between proportions were assessed with the chi-squ-
ared test. Overall survival (OS) was defined as the time from
transplantation to the date of last follow-up or death from
any cause. Leukemic-free survival (LFS) was calculated from
the date of CR to the recording of disease relapse or death
from any cause. Patients who died in CR were plotted as cen-
sored. The actuarial curve for OS was plotted corresponding
to the Kaplan-Meier method. P values <0.05 were consid-
ered statistically significant.
RESULTS
Response to treatment 
As shown in Table 1, the disease status and hematologic
features in the 61 patients were variable. The median pre-
leukemic free survival (pre-LFS) before FLAG chemothera-
py was 8.8 months (range, 0-56.5 months). 
Forty-nine patients were evaluated for response and the
clinical outcomes of FLAG chemotherapy as summarized in
Table 2. Twelve patients (19.7%) could not be evaluated for
clinical responses; specifically, 7 patients (11.4%) had TRM
and 5 patients could not undergo marrow examination due to
debilitating conditions.
Overall, 29 patients (47.5%) achieved a CR and 19 patients500 S.R. Lee, D.H. Yang, J.S. Ahn, et al.
(32.8%) had a resistant disease to FLAG chemotherapy. Pa-
tients with 1st or 2nd relapses had response rates 58.6 and
66.7%, respectively. However, patients with primary refrac-
toriness or relapse after HSCT showed lower response rates of
38.9 and 12.5%, respectively. Patients who had ≥6 months
duration of pre-LFS had relatively high CR rates compared
to those who had ≤6 months (71.4% vs. 33.3% respective-
ly, P=0.05). The CR rate was 50.9% in de novo AML, while
the CR rate was 16.7% in secondary AML. The patients with
de novo AML had higher response rates than those with sec-
ondary AML, although not statistically significance (P=0.08).
However, when patients were stratified by cytogenetic prog-
nostic group, the patients with favorable cytogenetics failed
to show a significant difference in therapeutic outcomes com-
pared to those with intermediate or poor cytogenetics. Also,
there were no statistical differences in CR rates according to
age (age <50 yr or age ≥50 yr) and disease status before FLAG
chemotherapy.
The median duration of survival of all patients was 14.3
months (range, 1.3-75.1 months) and the 3-yr probability
of OS was 29.8±7.1% (Fig. 1). After achieving CR in 29
patients, 6 patients underwent allogeneic HSCT and 18 pa-
Characteristics (%)
Age in years (range) 33.6 (20-70)
Gender (male/female)  35/26 (57.3/42.6)
WHO performance status 
0-1 40 (65.6)
2 19 (31.1)
3 2 (3.3)
Karyotypes (%)
Favorable 6 (9.8)
Intermediate 38 (62.3)
Poor 15  (24.6)
Not evaluated 2 (3.3)
Disease status 
First relapse after conventional chemotherapy 29 (47.5)
Second relapse after chemotherapy 6 (9.8)
Primary induction failure 18 (29.5)
Relapse after autologous HSCT 4 (6.6)
Relapse after allogeneic HSCT 4 (6.6)
Secondary leukemia from MDS  6 (9.8)
Pre-relapsed LFS (months) 8.8 (0-56.5)
Table 1. Patient characteristics 
HSCT, hematopoietic stem cell transplantation; MDS, myelodysplastic
syndrome; LFS, leukemic-free survival.
No.  CR (%) NR (%) NM (%) P value
Overall response 61 29 (47.5) 20 (32.8) 12 (19.7)
Age
≥50 26 11 (42.3) 8 (30.8) 7 (26.9) NS
<50 35 18 (51.4) 12 (34.3) 5 (14.3)
Disease status
First relapse 29 17 (58.6) 8 (27.6) 4 (13.8) 0.14
Second relapse 6 4 (66.7) 2 (33.3) 0
Primary refractory  18 7 (38.9) 7 (38.9) 4 (22.2)
Relapse after HSCT 8 1 (12.5) 3 (37.5) 4 (50.0)
Karyotype
Favorable 6 3 (50.0) 0 3 (50.0) 0.12
Intermediate 38 19 (50.0) 12 (31.6) 7 (18.4)
Poor 15 7 (46.7) 7 (46.7) 1 (6.7)
Disease
de novo 55 28 (50.9) 18 (32.7) 9 (16.4) 0.08
Secondary 6 1 (16.7) 2 (33.3) 3 (50.0)
Pre-LFS
≥6 months 14 10 (71.4) 1 (7.1) 3 (21.4) 0.05
<6 months 21 7 (33.3) 8 (38.1) 6 (28.6)
Table 2. Outcomes of FLAG chemotherapy in patients with AML
AML, acute myeloid leukemia; CR, complete remission; NR, non-remis-
sion; NM, non-measurable; SCT, stem cell transplantation; HSCT, hema-
topoietic stem cell transplantation; Pre-LFS, leukemic-free survival before
FLAG chemotherapy.
Fig. 1. The probability of leukemic free survival (LFS) and overall survival (OS) after FLAG chemotherapy in patients with relapsed or refrac-
tory AML (n=61).
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tients received consolidation chemotherapy. The remaining
five patients did not receive further therapy because of relapse
or poor PS. After consolidation, the median LFS after FLAG
chemotherapy was 17.1 months (range, 0.2-27.6 months)
and 17 patients are still in continuous CR with a median fol-
low-up of 7.59 months (range, 0.2-27.6 months).
Toxicity 
All patients experienced profound granulocytopenia. The
median recovery time for neutrophils (≥0.5×109/L) and
platelets (≥50×109/L) from the day chemotherapy com-
menced was 21 and 20 days, respectively. A median of 10
red cell units (range, 2-44 red cell units) were required. Non-
hematologic toxicity was mild-to-moderate; infection was
the most common side effect. The toxicities (≥grade 3) con-
sisted of infection (26.2%), mucositis (9.8%), hepatic dys-
function (8.1%) and gastro-intestinal dysfunction including
nausea and vomiting (11.4%) (Table 3).
The TRM was 11.4%; 5 patients died due to acute respi-
ratory failure from fungal pneumonia, one patient died due
to sepsis, and one patient died due to hemorrhagic compli-
cations after FLAG consolidation. Most cases of fungal pneu-
monia were caused by an invasive aspergillosis. 
DISCUSSION
The prognosis of patients with relapsed or refractory AML
is poor and has thus prompted a search for novel drugs or
drug combinations to improve the initial response rate and
prolong the survival. Indeed, several chemotherapy regimens
have been used in patients with refractory or relapsed AML
with response rates of 29-44% (17-19).
Recently, the FLAG regimen or with idarubicin has been
proposed as a more effective and relatively safe treatment for
relapsed or refractory patients with AML, characterized by
relatively high CR rates and a low TRM. In addition, FLAG
chemotherapy or with idarubicin is suggested to be a valu-
able remission induction regimen for poor risk leukemias
and myelodysplastic syndrome. The combination of fludara-
bine and ara-C is potentially a useful chemotherapeutic reg-
imen for the treatment of AML. Various studies have deter-
mined the clinical response of the FLAG regimen or with
idarubicin (9, 10, 12-14, 20) to be between 50 and 81%.
Yavuz et al. (21) and Pastore et al. (22) suggested that the
CR rate of FLAG-ida was 53.6 and 52.1% in the treatment
of the patients with relapsed and refractory AML, respective-
ly. In our study, the complete remission rate of FLAG with-
out idarubicin was 47.5%, similar to that of FLAG with idaru-
bicin. When compared with FALG-ida with respect to toxi-
city, the incidence of severe infection and mucositis (≥grade
3) was 26.2% and 9.8%, respectively. This is relatively low
compared with other studies that reported incidences of 45-
65% for relapsed and refractory patients.
When we classified the patients according to the duration
of pre-LFS before chemotherapy, the response rates were some-
what different (11, 12). We also found that disease type (de
novo or secondary) showed a slight trend in relation to CR
rates, although the relationship was not significant. In our
study, we found that the clinical response after the FLAG
regimen was greater in the first or second relapsed patients
(55 and 67%, respectively) than in primary refractory patients.
These results are consistent to those of previous studies (14,
23). We observed relatively lower CR rates in patients with
primary refractory (38.9%) or relapse after HSCT (12.5%).
On the other hand, we did not find that the patient’s age and
karyotyping risks had a significant influence on CR rates.
As with previous studies that have suggested that addition-
al therapy is required to achieve long term survival in respon-
sive patients, we found that the duration of remission after
FLAG chemotherapy remained short-term. Autologous or
allogeneic HSCT after FLAG chemotherapy represented the
best consolidation strategies for the responsive patients because
FLAG chemotherapy showed a low TRM and a high response
rate (20, 23-25). Following CR achievement, six patients
underwent allogeneic HSCT in this study. Five of these pa-
tients remained in CR at the time of analysis.
The toxicity of this regimen was acceptable, especially con-
sidering that most patients had been heavily pretreated. The
major cause of early mortality in TRM was fungal infections
(71.4%). There were reports that HEPA filters could pro-
vide the protection for highly immunocompromised patients
with hematologic malignancies and are also effective at con-
trolling outbreaks due to air contamination of aspergillosis
and candidiasis (26, 27). The situation of this study was quite
different because most patients were managed in regular
rooms after chemotherapy. However, the incidence of TRM
seemed to be acceptable and hematologic recovery was rela-
Hematologic toxicities Median days (range)
Non-hematologic toxicities (≥Grade 3) Number of patients (%)
ANC ≥500/μ L D+21 (12-57)
ANC ≥1,000/μ L D+21 (13-66)
Platelets ≥20,000/μ L D+18  (11-49)
Platelets ≥50,000/μ L D+20 (13-67)
PRC requirement, median 10 units (3-44)
GI disturbance (nausea/vomiting) 7 (11.4)
Hepatic dysfunction 5 (8.1)
Rash 1  (1.6)
Mucositis 6 (9.8)
Renal insufficiency 0
Diarrhea 2 (3.2)
Infections 16 (26.2)
Treatment-related mortality 7 (11.4)
Table 3. Hematologic and non-hematologic toxicities
ANC, absolute neutrophil counts; PRC, packed red blood cells.502 S.R. Lee, D.H. Yang, J.S. Ahn, et al.
tively fast, compared to the previous studies (12, 13, 15, 20,
28-30).
In conclusion, our results suggest that FLAG chemother-
apy is a well-tolerated regimen for relapsed or refractory AML
patients. In particular, FLAG chemotherapy may be especial-
ly useful for patients who have a sibling or unrelated donor
for performing allogeneic HSCT.
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